630407-52-2

Upstream product

• 50-00-0 formaldehyd 
• 76935-76-7 2-(3-ethoxyphenyl)ethylamine 
• 591-31-1 3-methoxy-benzaldehyde 
• 3179-09-7 1-methoxy-3-(2-nitrovinyl)benzene 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 57196-62-0 6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 942150-85-8 bis(6-methoxy-N-1,2,3,4-tetrahydroisoquinolinyl)methane 
• 59839-23-5 6-hydroxy-1,2,3,4-tetrahydroisoquinoline hydrobromide 
• 158984-83-9 N-tert-butoxycarbonyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 1429254-15-8 6-ethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 

Downstream Products

• 1429254-04-5 C₂₄H₂₅N₃O₃ 

Relevant academic research and scientific papers

SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer

Molecular knowledge of pure antagonism and systematic SAR study offered a direction for structural optimization of DIMN to provide nicotinamides as a novel series of AR antagonists. Nicotinamides with extended linear scaffold bearing sterically bulky alkoxy groups on isoquinoline end were synthesized for H12 displacement. AR binding affinity and molecular basis of antiandrogenic effect establish the optimized derivatives, 7au and 7bb, as promising candidates of second generation AR antagonists for advanced prostate cancer.